Real world efficacy and safety of nintedanib in idiopathic pulmonary fibrosis: A single center, observational study from India

Deepak Talwar¹, Deepak Kumar Prajapat¹, Dhruv Talwar²

¹Department of Internal Medicine, Metro Centre for Respiratory Diseases, Noida, Uttar Pradesh, India, ²Department of Pulmonary, Critical Care, Allergy and Sleep Medicine, JNMC, Savangi, Maharashtra, India

ABSTRACT

Background: Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis (IPF) has been established by multiple clinical trials. This study aims to assess the efficacy and safety of nintedanib in real-world IPF patients in India.

Methods: Clinical records of IPF patients (prescribed with nintedanib) visiting tertiary pulmonary care center, between June 2016 and December 2019, were analyzed retrospectively. Data were analyzed for forced vital capacity (FVC), Diffusing capacity of lung for carbon monoxide (DLCO), 6-min walk distance (6-MWD). Acute exacerbations and adverse events were also analyzed.

Results: A total of 76 IPF patients were prescribed with nintedanib. Drug was prescribed at 100 and 150 mg BD dose to 37 and 39 patients. Ten patients (13.1%), of which eight were over the age of 60 years, died during the study period. Only 42 patients visited for follow-up. Mean baseline FVC was 1.67 L and mean annualized absolute change in FVC and FVC % predicted was −0.07 L and −1.80%, respectively. Mean baseline DLCO was 37.21% and mean annualized absolute change in DLCO % predicted was −2.20%. At follow-up, 1 (2.38%), 17 (40.47%), and 24 (57.14%) patients were at Department of Internal Medicine stage I, II, and III, respectively. Acute exacerbations and adverse events were reported by 48 and 6 patients, respectively.

Conclusion: Our results support the findings from previous studies, that nintedanib leads to annual decline in parameters such as FVC and DLCO and increased 6-MWD. It was found to be well tolerated in the Indian patients with IPF.

KEY WORDS: Adverse event, diffusing capacity for carbon monoxide, forced vital capacity, idiopathic pulmonary fibrosis, nintedanib

INTRODUCTION

Idiopathic pulmonary fibrosis (IPF) with the prevalence varying from 2 to 9 per 100,000 population, is a chronic, progressive interstitial lung disease (ILD) of unknown etiology and is associated with rapid decline in lung function. The disease occurs predominantly in the elderly and occurs more commonly in people exposed to certain risk factors. IPF has a poor prognosis with a median survival time of around 2–3 years. Progression...
The aim of therapy in IPF is to alleviate symptoms and slow the disease progression. While no drug “cures” IPF, antacids help in relieving reflux symptoms and antifibrotics (pirfenidone and nintedanib) decelerate the disease progression. Nintedanib is a potent small-molecule tyrosine kinase inhibitor of vascular endothelial growth factor receptor, fibroblast growth factor receptor, and platelet-derived growth factor receptor. The efficacy and safety of nintedanib in IPF were assessed in one phase II trial (TOMORROW, n = 432) and two identical phase III (INPULSIS-1 and INPULSIS-2) trials. The trials demonstrated that nintedanib slowed disease progression by significantly reducing the annual rate of decline in FVC. It may also reduce the incidence of acute exacerbations and improve health-related quality of life. Diarrhea was the most common adverse effect of nintedanib, however, most episodes were mild to moderate, and were manageable by dose reduction and treatment interruption. While the subgroup analyses of INPULSIS showed that nintedanib is effective in broad spectrum of IPF patients typically, in clinical practice, the published literature on its real-world use is limited. Recently, an Indian study describing the effect of nintedanib in IPF patients in clinical practice was conducted, however, the sample size was very small (n = 20). Therefore, the present study was conceptualized in larger sets of IPF patients to assess the efficacy and safety of nintedanib in real-world settings in India.

METHODS

This was a real-world retrospective study conducted at single center in India.

Study population
Data from clinical records of IPF visiting the tertiary pulmonary care center in North India between June 2016 and December 2019, were analyzed retrospectively. Data were digitized in a specially designed case record form, after removing patient-identifier information. All complete patient records were used for the analysis. Patients diagnosed with IPF based on the European Respiratory Society/American Thoracic Society guidelines, and prescribed nintedanib, were included in the analysis. Patients without any follow-up visits were excluded.

Since patients were followed up in ILD Clinic at the center, recruitment and follow-up was done as per existing protocol where diagnosis is established after multidisciplinary discussion and all patients are followed up every 8–12 weeks with routine and lung functions evaluation. The ethical approval was taken from the Institutional Ethics Committee for the patient data analysis.

Outcomes assessed

Primary outcomes
Baseline and follow-up data were available, and analyzed for FVC, diffusing capacity for carbon monoxide (DLCO), 6-MWD. The changes in these parameters over 1-year period according to age and last dosage regimen were assessed.

Secondary outcomes
Number of episodes of acute exacerbations, and adverse events (reported by patients or based on lab investigations) were analyzed.

Data analysis
To ensure a more reliable interpretation of changes in various parameters, we included, in respective analyses, only those patients for whom there was a gap of at least 6 months between the first and the last observations. In these subsets of patients, data were annualized based on first and last available values.

Data analysis was done using Python 3.7.3, R studio 1.2.1335 and Microsoft Excel (version 16.31). Descriptive statistics were presented in the form of categorical and continuous variables. Categorical variables (like age, gender) were expressed as percentages. Continuous variables (like FVC, DLCO, 6-MWD) were expressed as means, and the annualized rate was calculated on the linear assumption by using: Y = m × x + c, where m is the slope of the line and calculated as (value2-value1)/(date2-date1), c is the intercept of line and calculated as (date2 × value1 × date1*value2)/(date2-date1), y is the value of the variable (FVC, DLCO, 6-MWD) and x is the date.

RESULTS

A total of 76 IPF patients’ data were available for the analysis. The mean age of the patient population was 63.1 years, and 57.9% were males. Detailed baseline demographic and clinical characteristics are presented in Table 1. The total duration of nintedanib treatment was 23.2 months. Ten patients (13.1%), of which eight were over the age of 60 years, died during the study period, due to progression of IPF and other associated comorbidities.

Nintedanib treatment
The treatment of the IPF patients was done using two doses of nintedanib. The basis of choosing 100 mg and 150 mg dose of nintedanib was as per the clinical practice (tolerance and liver functions) followed for the treatment of IPF patients in India. In our clinical practice,
for patients who have low body weight, instead of the usual approach of starting with 150 mg BID and reducing to 100 mg BID if needed, we initiate nintedanib treatment at 100 mg BID, and increase the dose to 150 mg BID at the first follow-up (within 1–2 months), if 100 mg dose is tolerated well. In case 150 mg BID dose is not tolerated, we reduce the dose back to 100 mg BID. Although not supported by recommendations, in our experience, such an approach tends to improve patient compliance to therapy.

The mean duration of exposure to nintedanib (n = 74) was 23.3 months. At first visit at our center, nintedanib was prescribed at a starting dose of 100 mg BD to 37 patients, and 150 mg BD to 39 patients. At the time of last observation, the initial dose was unchanged in 57 patients, while 19 patients’ dose was modified during treatment (from 100 mg BID to 150 mg BID in 11 patients; 150 mg BID to 100 mg BID in 8 patients).

Changes in forced vital capacity

Out of the 76 patients, 42 patients had FVC data available for at least one follow-up visit after baseline FVC assessment. Total 42 patients, for whom there was a gap of at least 6 months between the first and the last FVC measurements, were included in the analysis. Mean baseline FVC was 1.7 L; mean duration between first and last measurements was 20.2 months (median 18.1 months).

Mean annualized absolute change in FVC and FVC % predicted from baseline till follow-up was −0.07 L and −1.80% respectively. Age and dose regimen-wise changes in FVC are presented in Table 2. Out of these 42 patients, 20 (47.6%) patients showed either an improvement or a decline of <5% in FVC % predicted, indicating stable disease. The regression analysis was applied to the data to find the association of the variables with the disease stability. Variables included in the univariate analysis were age, gender, dose, exposure to nintedanib (duration in months), GAP stage, and FVC. The reason for including these variables in the multivariate analysis was based on the biological plausibility, statistical (variables significant from univariate analysis), and clinical significance. On multivariate analysis, it was found that dose regimen usage (150 mg BID), GAP index stage III and high baseline FVC was associated with unstable disease (with adjusted odds ratio 2.83, 2.06, and 1.96 respectively). However, the results were found to be statistically insignificant (P > 0.05) [Table 3].

Changes in DLCO

We analyzed DLCO data of only those (n = 37) patients in whom there was a gap of at least 6 months between the first and last available observations. Mean baseline DLCO was 37.2%; mean and median follow-up duration was 20.0 and 17.1 months, respectively. The mean annualized absolute change in DLCO % predicted was −2.2%. Decline in DLCO % predicted was comparatively lesser in the patients aged ≤60 years (−1.3%) and those on 150 mg BD dose at the last observation [Table 4].

Changes in GAP index stage over treatment

GAP index for over at least 6 months was available for 69 patients at baseline and 42 patients at the time of follow-up. At baseline, half of the patients (35, 50.7%) had GAP index stage of III followed by 32 (46.4%) at stage II and 2 (2.9%) at stage I. At the time of follow-up, 1 (2.4%), 17 (40.5%), and 24 (57.1%) patients were at GAP Index Stage I, II, and III, respectively [Figure 1].

Table 1: Baseline demographic and clinical characteristics of patient population

| Characteristics (n, number of patients with available data) | Details |
|-----------------------------------------------------------|---------|
| Age (years) (n=76), mean (SD)                             | 63.1 (12.5) |
| <60                                                       | Range (30-86) |
| 60-70                                                     | 25 (32.9) |
| >70                                                       | 24 (31.6) |
| Gender (n=76), n (%)                                      | Male 44 (57.9) |
|                                                          | Female 32 (42.1) |
| Duration of nintedanib treatment (months) (n=74), mean (SD)| 23.3 (24.0) |
| TLC (L) (n=23), mean (SD)                                 | 3.2 (1.0) |
| FVC (L) (n=42), mean (SD)                                 | Range (0.6-3.3) |
| FVC % predicted (%) (n=42), mean (SD)                     | 57.0 (20.0) |
| DLCO (%) (n=37), mean (SD)                                | Range (24.3-110.6) |
| Comorbidities (n=76), n (%)                               | Type 2 diabetes 38 (50.0) |
| Hypertension                                             | 34 (44.7) |
| Coronary artery disease                                  | 19 (25.0) |
| Gastro-esophageal reflux disease                         | 17 (22.4) |
| Hypothyroidism                                           | 16 (21.1) |
| Osteoporosis                                             | 15 (19.7) |
| Obstructive sleep apnea                                  | 8 (10.5) |
| GAP index (n=69), n (%)                                   | Stage I 2 (2.9) |
|                                                          | Stage II 32 (46.4) |
|                                                          | Stage III 35 (50.7) |
| 6-MWD test (m) (n=27), mean (SD)                          | 266.1 (89.6) |
|                                                           | Range (112-532) |

TLC: Total lung capacity, FVC: Forced vital capacity, DLCO: Diffusing capacity for carbon monoxide, SD: Standard deviation, 6-MWD: 6 min walk distance GAP: Gender-Age-Physiology Index

Figure 1: Distribution of patients in GAP index Stage I, II, and III at baseline and follow-up
Table 2: Changes in forced vital capacity over one year in the patient population

| Variables               | n  | Baseline FVC | FVC after 1 year | Change in FVC over 1-year |
|-------------------------|----|--------------|------------------|-------------------------|
|                        |    | Absolute (L) | Percentage predicted mean (SD) | Absolute (L) | Percentage predicted mean (SD) | Absolute (L) | Percentage predicted mean (SD) |
| Age (years) ≤60        | 20 | 1.5 (0.6)    | 47.2 (15.7)      | 1.4 (0.5)    | 44.2 (14.1)      | −0.11 (0.21) | −3.0 (6.5)       |
|                        |    | Range (0.7-3.1) | Range (24.3-74.7) | Range (0.7-2.4) | Range (23.4-68.7) | Range (−7.0-3.3) | Range (−17.1-12.6) |
| >60                    | 22 | 1.9 (0.7)    | 65.8 (19.7)      | 1.8 (0.7)    | 65.1 (20.0)      | −0.03 (0.22) | −0.7 (8.2)       |
| Dose regimen (at last observation) (mg BID) |    | Absolute (L) | Percentage predicted mean (SD) | Absolute (L) | Percentage predicted mean (SD) | Absolute (L) | Percentage predicted mean (SD) |
| 100                    | 20 | 1.7 (0.7)    | 53.9 (20.6)      | 1.6 (0.7)    | 53.0 (22.2)      | −0.06 (0.23) | 0.9 (7.3)        |
|                        |    | Range (0.6-3.1) | Range (28.6-110.6) | Range (0.7-3.1) | Range (23.4-109.9) | Range (−0.7-0.5) | Range (−17.1-21.4) |
| 150                    | 22 | 1.7 (0.7)    | 59.7 (19.6)      | 1.6 (0.6)    | 57.1 (18.5)      | −0.08 (0.21) | −2.63 (7.6)      |

FVC: Forced vital capacity, SD: Standard deviation

Table 3: Details of the multivariate regression analysis

| Parameters | Adjusted odds | CI (2.5%-97.5%) | P  |
|------------|--------------|-----------------|----|
| Age        | 0.99         | 0.9-1.1         | 0.738 |
| Gender     |              |                 |    |
| Female     | 1            | 1               | 0.307 |
| Male       | 0.3          | 0.03-2.9        |    |
| Dose (mg)  |              |                 |    |
| 100        | 1            | 1               | 0.158 |
| 150        | 2.83         | 0.7-12.7        | 0.78 |
| Exposure (duration in months) | 1 | 0.9-1.0 | 0.78 |
| GAP stage  |              |                 |    |
| Stage I and II | 1 | 1 | 0.508 |
| Stage III  | 2.06         | 0.3-19.4        |    |
| FVC at baseline | 1.96 | 0.5-8.3 | 0.335 |

CI: Confidence interval, FVC: Forced vital capacity, GAP: Gender-Age-Physiology Index

6-Minute walk distance (6-MWD)

A total of 42 patients underwent analysis for 6-MWD. Mean baseline 6MWD was 266.1 m and at the time of follow-up, it was 291.4 m. Therefore, the mean absolute change in MWD was 25.3 meters. Patients aged ≤60 years and those who were on 100 mg BID showed a higher decline in 6-MWD as compared to the other categories [Table 5].

Adverse events

Acute exacerbations

Episodes of acute worsening of dyspnea and lung function, without an identifiable cause were termed as acute exacerbations. Seventy-two (94.8%) patients had a history of acute exacerbations prior to starting the nintedanib therapy. Forty-eight (63.2%) patients reported acute exacerbations over the study period [Table 6]. Only mild to moderate exacerbations treated on OPD basis are being taken for evaluation. Since the window of repeat evaluations was 4–8 weeks they were conducted during that period only. These exacerbations required increase oxygen demand and antibiotics with short course of steroids.

Treatment-related adverse events

A total of 6 adverse events (all gastrointestinal) were reported by the patients. The most common adverse event was diarrhea. One patient discontinued the drug permanently; others could be managed by reducing the dose of nintedanib, and symptomatic management, including the use of loperamide [Table 6].

DISCUSSION

The study provides insights related to the IPF patients met in clinical practice in India. While clinical trials provide a higher level of evidence, the participants are more selected and may not include all types of patients in whom the drug will be finally used in clinical practice. Real-world evidence thus fills up this gap and provides data on a drug’s safety and efficacy in a wider set of patients. The findings of the present study revealed that nintedanib bear potential in reducing the %FVC and DLCO and improving 6-MWD in IPF patients. Further, only 6 patients reported adverse events which were also mild and were managed by dose reduction. This reflected the tolerability of nintedanib in IPF patients. Thus, nintedanib can be used for alleviating the symptoms experienced in IPF.

Our study involves a relatively large set of IPF patients and provides important information on the characteristics of Indian IPF patients seen in clinical practice. There are differences when we compare our study’s population with that of INPULSIS trials. Our patients were relatively young (mean age 63 years vs. 67 years). FVC % predicted was substantially lower than that in INPULSIS trials. Our patients were relatively young (mean age 63 years vs. 67 years). FVC % predicted was substantially lower than that in INPULSIS trials. Our patients were relatively young (mean age 63 years vs. 67 years). FVC % predicted was substantially lower than that in INPULSIS trials. Our patients were relatively young (mean age 63 years vs. 67 years). FVC % predicted was substantially lower than that in INPULSIS trials. Our patients were relatively young (mean age 63 years vs. 67 years). FVC % predicted was substantially lower than that in INPULSIS trials. Our patients were relatively young (mean age 63 years vs. 67 years). FVC % predicted was substantially lower than that in INPULSIS trials.
In the INPULSIS trials, majority of the patients were in GAP stage I, followed by stage II and III (47.2%, 46.1%, and 14.5% in GAP stages I, II, and III, respectively). This is in contrast with our data wherein we found that majority of patients were in GAP stage III, followed by stage II, and a very few patients in stage I (2.9%, 46.4%, and 50.7% in GAP stages I, II, and III, respectively). This too can be attributed to late presentation of Indian IPF patients, owing to delays in diagnosis. It would not be surprising then if the average survival of Indian IPF patients was found to be lower than their western counterparts. It may be somewhat heartening, however, to note that nintedanib provides a similar beneficial effect on FVC decline in patients at GAP stage I vs. stage II/III, according to a post hoc analysis of INPULSIS trials.[11]

When compared with a few other real-world studies with nintedanib in IPF across the world [Table 7], the patients in our study, in general, had lower age, lower FVC % predicted, and similar rates of comorbid conditions (except for diabetes, which was higher in Indian patients). DLCO% was found to nearly same with respect to other studies. The proportion of males in our study was lower than that in INPULSIS trials, and in other real-world studies, although in our study too males outnumbered females. It is important to note, however, that despite small differences in the patient characteristics, our findings were generally similar to other real-world studies— nintedanib seems to stabilize the lung function in IPF in majority of patients and is well tolerated. This supports that fact that nintedanib is efficacious in a wide variety of IPF patients.

Recently, a study on tolerability of another antifibrotic agent, i.e., pirfenidone has been conducted for assessing its effect on the survival in IPF. The results revealed that pirfenidone was well-tolerated among the patients but showed increase in survival only with the full dose. The annualized fall in % predicted FVC was found to be similar across both the doses. The most common adverse events reported with this drug were anorexia, dyspepsia,
and nausea, which were in accordance with the previous real-world studies. Conversely, another research reported that Pirfenidone did not show any significant beneficial effect in IPF patients.

Our study adds to a previous, relatively small, but important Indian study that provided initial data on the Indian experience of nintedanib use in 20 patients with IPF. The mean age (60 years) and FVC % predicted (50.4%) in that study are similar to what we observed in our patients. Importantly, although diarrhea was the most common adverse effect in both the studies, it was manageable with dose reductions. Only one patient in our study permanently discontinued the drug because of diarrhea.

**Study strengths and limitations**

This is the largest real-world study from India, assessing the characteristics of IPF patients, and effectiveness and safety of nintedanib in IPF patients. However, as with most other real-world studies, the limitations include retrospective data collection and heterogeneity of patients. In addition, compliance to therapy and quality of life was not assessed. Furthermore, as it is single-center study conducted in northern India, the results could not be generalized to the whole population.

**CONCLUSION**

The study provides the largest data from India, of real-world use of nintedanib in IPF. The results indicate that Indian patients are, on an average, younger than their western or Japanese counterparts. Indian patients tend to have worse FVC % predicted at the time of diagnosis. This might be attributable to delay in seeking treatment and/or in making an appropriate diagnosis, which calls for an increase in the awareness of ILDs in general public and physicians. Our results support the findings from clinical trials and other real-world studies, that nintedanib is effective in slowing down IPF progression, and is generally well tolerated.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**REFERENCES**

1. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: Idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;183:788-824.

2. Kolb M, Collard HR. Staging of idiopathic pulmonary fibrosis: Fast, present and future. Eur Respir Rev 2014;23:220-4.

---

**Table 7: Comparison of real-world Indian studies with western counterparts**

| Variables                        | Americas USA Galli et al. [22] | Europe UK Toellner et al. [19] | Germany Bonella et al. [18] | Germany Brunner et al. [17] | Greece Tzouvelekis et al. [16] | Japan Nakamura et al. [15] | Japan Kataoka et al. [14] | Current study | Mullerpattan et al. [7] |
|----------------------------------|-------------------------------|--------------------------------|-----------------------------|-----------------------------|-------------------------------|-----------------------------|-----------------------------|---------------|------------------------|
| Number of patients               | 57                            | 187                            | 62                           | 64                           | 94                            | 22                          | 37                          | 76*           | 20                     |
| Clinical characteristics         |                               |                                |                              |                              |                               |                              |                              |               |                        |
| Male, n (%)                      | 34 (59.6)                     | 142 (76)                       | 48 (77)                      | 55 (85.9)                    | 72 (76.6)                     | 20 (91)                      | 31 (84)                     | 44 (57.9)     | 15 (75)                |
| Age (years) mean (SD)            | 71 (8)                        | 72 (8)                         | 71 (8)                       | 70.3 (6.8)                   | 73.8 (7.8)                    | Median 71.5                 | Median 70.4 (6.5)            | 63.1 (12.5)   | 60.00                  |
| Comorbidities, n (%)             |                               |                                |                              |                              |                               |                              |                              |               |                        |
| Coronary artery disease          | 14 (24.6)                     | 43 (23)                        | 8 (13)                       | 21 (32.8)                    | 20 (21.3)                     | -                           | -                           | 19 (25.0)     | -                      |
| Diabetes mellitus                | 15 (26.3)                     | 37 (20)                        | 9 (14.5)                     | 16 (25.0)                    | 18 (19.1)                     | -                           | -                           | 38 (50.0)     | -                      |
| Gastroesophageal reflux disease  | 31 (54.4)                     | 19 (10)                        | 7 (11)                       | 21 (32.8)                    | 38 (40.4)                     | -                           | -                           | 17 (22.4)     | -                      |
| Obstructive sleep apnoea syndrome | -                             | 4 (6)                          | 9 (14.1)                     | -                            | -                             | -                           | -                           | 8 (10.5)      | -                      |
| Baseline lung function (efficacy parameters) |                   |                                |                              |                              |                               |                              |                              |               |                        |
| DLCO %, mean (SD)                | 35 (13)                       | 43.9 (15)                      | 40 (10)                      | 37 (10)                      | 44.4 (14.5)                   | Median 64.0                 | -                           | 37.2 (17.5)   | -                      |
| FVC % predicted, mean (SD)       | 66 (17)                       | 81.1 (19.8)                    | 64 (17)                      | 71 (21)                      | 68.1 (18.3)                   | Median 63.0                 | -                           | 57.0 (20.0)   | 1.43 L (mean predicted: 50.4%) |
| Adverse events (safety parameters), n (%) |                               |                                |                              |                              |                               |                              |                              |               |                        |
| Diarrhea                         | 30 (52.6)                     | 185 (98.9)                     | 39 (62.9)                    | 21 (32.8)                    | 52 (55.3)                     | 16 (73)                     | -                           | 4 (50)        | -                      |
| Nausea/vomiting                  | 20 (33.3)                     | 123 (65.8)                     | 16 (25.8)                    | 2 (3.1)                      | 29 (30.8)                     | 2 (9)                       | -                           | -             | -                      |
| Dyspepsia/abdominal pain, bloating and wind | 3 (5.3)                     | 58 (31.0)                     | 4 (6.5)                      | -                            | 9 (9.5)                       | -                           | 1 (12.5)                    | -             | -                      |
| Reduced appetite/anorexia        | 3 (5.3)                       | 65 (34.8)                     | 24 (38.7)                    | -                            | 18 (19.1)                     | -                           | 1 (12.5)                    | -             | -                      |
| Constipation                     | -                             | -                              | -                            | -                            | -                             | -                           | 1 (12.5)                    | -             | -                      |
| Abdominal fullness               | -                             | -                              | -                            | -                            | -                             | -                           | 1 (12.5)                    | -             | -                      |
| Dose reduction, n (%)            | 12 (21.1)                     | 22 (12)                        | 21 (34)                      | 8 (13)                       | -                             | -                           | 8 (10.5)                    | 4 (20)        | -                      |
| Drug discontinuation, n (%)      | 15 (26.3)                     | 39 (21)                        | 25 (40)                      | -                            | 20 (21.2)                     | 12 (55)                     | -                           | 4 (20)        | -                      |
| Acute exacerbation on therapy, n (%) | 6 (10.5)                     | -                              | 11 (17)                      | -                            | -                             | -                           | 48 (63.2)                   | -             | -                      |

*Our real-world study. DLCO: Diffusing capacity for carbon monoxide, FVC: Forced vital capacity, SD: Standard deviation
3. Raghu G, Rochwerg B, Zhang Y, Garcia CA, Azuma A, Behr J, et al. An official ATS/ERS/JRS/ALAT clinical practice guideline: Treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. Am J Respir Crit Care Med 2015;192:e3-19.

4. Wollin L, Wex E, Pautsch A, Schnapp G, Hostetter KE, Stowasser S, et al. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur Respir J 2015;45:1434-45.

5. Bendstrup E, Wuyts W, Alfaro T, Chaudhuri N, Cornelissen R, Kreuter M, et al. Nintedanib in idiopathic pulmonary fibrosis: Practical management recommendations for potential adverse events. Respiration 2019;97:173-84.

6. Rodríguez-Portal JA. Efficacy and safety of nintedanib for the treatment of idiopathic pulmonary fibrosis: An update. Drugs R D 2018;18:19-25.

7. Mullerpattan JB, Porwal SH, Sarkar TA, Wagh HD, Udwarad ZF. Use of nintedanib in patients with idiopathic pulmonary fibrosis: Initial Indian experience. Lung India 2019;36:465-6.

8. Suvarna VR. Real world evidence (RWE) - Are we (RWE) ready? Perspect Clin Res 2018;9:61-3.

9. Dhooria S, Sehgal IS, Agarwal R, Aggarwal AN, Behera D. Knowledge, attitudes, beliefs and practices of physicians regarding idiopathic pulmonary fibrosis and the impact of a continuing medical education program. J Assoc Physicians India 2017;63:30-6.

10. Natarajan S, Subramanian P. Idiopathic pulmonary fibrosis: A study of 46 patients from western India: Clinical presentations and survival. Turk Thorac J 2015;16:114-20.

11. Ryerson C, Kolb M, Richeldi L, Lee J, Wachtlin D, Stowasser S, et al. Effects of nintedanib in patients with idiopathic pulmonary fibrosis by GAP stage. ERJ Open Research. 2019;5(2):00127-2018.

12. Galli JA, Pandya A, Vega-Olivo M, Dass C, Zhao H, Criner GJ. Pirfenidone and nintedanib for pulmonary fibrosis in clinical practice: Tolerability and adverse drug reactions. Respirology 2017;22:1171-8.

13. Toellner H, Hughes G, Beswick W, Crooks MG, Donaldson C, Forrest J, et al. Early clinical experiences with nintedanib in three UK tertiary interstitial lung disease centres. Clin Transl Med 2017;6:41.

14. Bonella F, Kreuter M, Hagmeyer I, Neurohr C, Keller C, Kohlhaeufl MJ, et al. Insights from the German compassionate use program of nintedanib for the treatment of idiopathic pulmonary fibrosis. Respiration 2016;92:98-106.

15. Brunnerer E, Wälcher J, Tenenbaum S, Hausmanns J, Schulze K, Seiter M, et al. Real-world experience with nintedanib in patients with idiopathic pulmonary fibrosis. Respiration 2018;95:301-9.

16. Tzouvelekis A, Karapitsakos T, Kontou M, Granitsas A, Malliou I, Anagnostopoulos A, et al. Safety and efficacy of nintedanib in idiopathic pulmonary fibrosis: A real-life observational study in Greece. Pulm Pharmacol Ther 2018;49:61-6.

17. Nakamura M, Okamoto M, Fujimoto K, Ebata T, Tominaga M, Nouno T, et al. A retrospective study of the tolerability of nintedanib for severe idiopathic pulmonary fibrosis in the real world. Ann Transl Med 2019;7:262.

18. Kataoka K, Taniguchi H, Kimura T, Yokoyama T, Matsuda T. Effect of nintedanib on multidimensional evaluation in patients with IPF. Diffuse Parenchymal Lung Disease. 2017

19. Dhooria S, Agarwal R, Sehgal IS, Prasad KT, Muth V, Garg M, et al. A real-world study of the dosing and tolerability of pirfenidone and its effect on survival in idiopathic pulmonary fibrosis. Sarcoidosis Vascul Diffuse Lung Dis 2020;37:148-57.

20. Suraj KP, Kumar NK, Jyothi E, Narayan KV, Biju G. Role of pirfenidone in idiopathic pulmonary fibrosis – A longitudinal cohort study. J Assoc Physicians India 2016;64:36-41.